Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Organovo Holdings Inc    ONVO

ORGANOVO HOLDINGS INC (ONVO)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
1.15(c) 1.09(c) 1.13(c) 1.1(c) 1.09(c) Last
1 369 803 739 955 753 411 1 051 491 808 117 Volume
-6.50% -5.22% +3.67% -2.65% -0.91% Change
More quotes
Financials ($)
Sales 2018 4,83 M
EBIT 2018 -35,9 M
Net income 2018 -36,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 8,07 M
EBIT 2019 -33,7 M
Net income 2019 -34,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 24,1x
Capi. / Sales2019 14,4x
Capitalization 117 M
More Financials
Company
Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications.It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be... 
More about the company
Surperformance© ratings of Organovo Holdings Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ORGANOVO HOLDINGS INC
02/09FRIDAY SECTOR LAGGARDS : Precious Metals, Biotechnology Stocks
AQ
02/09ORGANOVO : reports 3Q loss
AQ
02/08ORGANOVO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/08ORGANOVO HOLDINGS, INC. : Results of Operations and Financial Condition, Financi..
AQ
02/08Organovo Announces Fiscal Third-Quarter 2018 Results; Company Updates Full-Ye..
GL
02/08ORGANOVO HOLDINGS INC : Organovo Holdings, Inc. to Host Earnings Call
AC
01/18Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Resul..
GL
2017ORGANOVO : Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeut..
AQ
2017Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeu..
GL
2017ORGANOVO HOLDINGS, INC. (NASDAQ : ONVO) Files An 8-K Departure of Directors or C..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/18Zacks Investment Research Downgrades Organovo $ONVO to Hold  
02/17Organovo downgraded by Zacks Investment Research to hold.  
02/15Jefferies Group Raises Organovo FY2018 Earnings Estimates to ($0.33) EPS (Pre.. 
02/14$FLCR .0083 CAN RUN 1000% no koolaid. Do ur DD folks, insiders own 40% of the.. 
02/14$FLCR .0083 CAN RUN 1000% no koolaid. Do ur DD folks, insiders own 40% of the..
2
More tweets
Qtime:173
News from SeekingAlpha
02/09HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (2/9/2018) 
02/09Organovo registers $100M mixed shelf offering 
02/08Organovo Holdings' (ONVO) CEO Taylor Crouch on Q3 2018 Results - Earnings Cal.. 
02/08Organovo Holdings beats by $0.02, misses on revenue 
02/07Notable earnings after Thursday?s close 
Chart ORGANOVO HOLDINGS INC
Duration : Period :
Organovo Holdings Inc Technical Analysis Chart | ONVO | US68620A1043 | 4-Traders
Technical analysis trends ORGANOVO HOLDINGS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,50 $
Spread / Average Target 129%
EPS Revisions
Managers
NameTitle
Taylor J. Crouch President, Chief Executive Officer & Director
Kirk D. Malloy Chairman
Craig S. Kussman Chief Financial Officer
Sharon Collins Presnell Chief Scientific Officer
James T. Glover Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ORGANOVO HOLDINGS INC-15.67%117
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227